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ABSTRACT  
 
Objective: Adverse events (AEs) are health related events, reported by participants in 
clinical trials. We describe AEs  in the PACE trial of treatments for chronic fatigue 
syndrome (CFS) and baseline characteristics associated with them.  
Methods:  AEs were recorded  on three occasions over one year in 641 participants. We 
compared the numbers and nature of AEs between treatment arms of specialist medical 
care (SMC) alone, or SMC supplemented by adaptive pacing therapy (APT), cognitive 
behaviour therapy (CBT) or graded exercise therapy (GET). We examined associations 
with baseline measures by  binary logistic regression analyses, and compared the 
proportions of participants who deteriorated by clinically important amounts. 
Results:  Serious adverse events and reactions were infrequent. Non-serious adverse 
events were common; the median (quartiles) number was 4 (2, 8) per participant, 
with no significant differences between treatments (p = 0.47). A greater number of 
NSAEs was associated with recruitment centre, and baseline physical symptom count, 
body mass index, and depressive disorder. Physical function deteriorated in 39 (25%) of 
participants after APT, 15 (9%) after CBT, 18 (11%) after GET, and 28 (18%) after SMC 
(p < 0.001), with no significant differences in worsening fatigue.  
Conclusions: The numbers of adverse events  did not  differ significantly between trial 
treatments, but physical deterioration occurred most often after APT. The reporting of 
non-serious adverse events  may reflect the nature of the illness rather than the effect of 
treatments.  Differences between centres suggest that both standardisation of 
ascertainment methods and training are important when collecting adverse event data. 
 
Keywords: Adverse events, body mass index, chronic fatigue syndrome, depression, 
medically unexplained symptoms 
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Introduction  
 
Clinical trials frequently attribute health problems that arise during a trial to the 
intervention. But, when health problems typically remit and relapse, the attribution of 
all new health problems to the intervention may be misleading. This study aims to 
explore this issue in patients with chronic fatigue syndrome (CFS) who participated in 
a treatment trial. 
Adverse events reported by participants in clinical trials of treatments may be 
considered to be clinically serious or not, and to be reactions to trial treatments or 
not. Few studies have examined the associations and predictions of adverse events 
in trials. Several trials have suggested a relationship between the reporting of 
adverse events and negative affect; anxiety [1] depression [2] and neuroticism [3]. 
Female and introverted participants of phase 1 medical trials are more likely to report 
adverse events than males and extroverts [4]. Physical symptoms at baseline 
predicted having a treatment related adverse reaction in an antidepressant controlled 
trial [5]. As well as this small literature regarding adverse events in trials, there are 
well established associations between reporting physical symptoms, outside of trials, 
and both mood disorders [6-10] and symptom burden [11].  
Chronic fatigue syndrome (CFS) is characterised by long-standing disabling 
fatigue and other symptoms that have no alternative medical or psychiatric 
explanation [12]. Its nosological status and aetiology are uncertain [13]. CFS is 
associated with  functional somatic syndromes such as irritable bowel syndrome and 
fibromyalgia [14]. Treatments recommended by the National Institute of Healthcare 
and Clinical Excellence (NICE) include cognitive behaviour therapy (CBT) and 
graded exercise therapy (GET) [15], but patient organisations have expressed 
concern about their efficacy and safety [16].  
The PACE trial was a four arm randomised trial, which was designed to 
compare three therapies each added to specialist medical care (SMC) against SMC 
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alone to determine both efficacy and safety [17]. The trial found that two therapies, 
CBT and GET, were more effective than adaptive pacing therapy (APT), when any of 
these therapies were added to SMC, and were more effective than SMC alone [17]. 
While CBT and GET were designed to be rehabilitative, the goal of APT was to 
optimise adaptation to the illness by planning and pacing activities to avoid or reduce 
fatigue [17]. The trial measures of safety included systematic assessments of 
adverse events (AE), which occur uncommonly in trials of behavioural interventions 
[18]. We have already reported that there were few serious adverse events (SAEs) 
and even fewer serious adverse reactions (SARs), the numbers of which did not 
differ significantly across treatment arms [17]. We have also reported various 
measures of deterioration, but not whether there are any differences across 
treatment arms in the proportions of participants who deteriorated in the two primary 
outcomes by a clinically important amount [17]. This paper reports the more 
commonly reported non-serious adverse events (NSAEs), compares their frequency 
between treatment arms, and also identifies baseline factors associated with 
reporting larger numbers of NSAEs [17, 19]. On the basis of the previous literature, 
we hypothesised that NSAEs would be associated with female sex, a larger number 
of physical symptoms at baseline, and both depressive and anxiety disorders present 
at baseline. To our knowledge there has been no previous study examining 
associations of NSAEs in a trial of treatments for CFS or functional somatic 
syndromes.  
 
Methods 
Outline of the PACE trial 
This report uses data from the PACE trial, relevant aspects of which are described; 
more comprehensive accounts are available in the protocol [19], and the primary 
paper [17]. The PACE trial recruited 641 patients from secondary care clinics with a 
diagnosis of CFS, using the Oxford criteria, which require six or more months of 
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disabling fatigue, with fatigue being the principal symptom, and no alternative, 
explanatory diagnosis [20]. Participants were randomly allocated to one of four 
treatment arms consisting of specialist medical care (SMC) alone or SMC with one of 
APT, CBT or GET. Randomisation to the four treatment arms was stratified by 
centre, co-morbid depressive disorder, and different CFS and myalgic 
encephalomyelitis (ME) criteria [12, 21]. Following randomisation, participants 
received up to 15 sessions of therapy (if allocated to a therapy arm) and at least 3 
sessions of SMC. 
All consecutive new outpatients from six secondary care CFS clinics in 
England and Scotland with a clinical diagnosis of CFS were clinically assessed for 
eligibility and if they agreed  were screened by a research assistant (RA) for eligibility 
and consent for the trial. RAs were either nurses or psychologists, who were 
independent of clinical staff, but were not masked to treatment arms, this being 
impractical to achieve. There was only one RA per centre, but over the trial period, 
RAs left and were replaced in some centres. Recruitment commenced in March 2005 
and was completed by Nov 2008. Follow-up was up to one year from randomisation. 
Inclusion criteria were meeting Oxford research diagnostic criteria for CFS 
[20], a Chalder Fatigue Questionnaire binary score of 6 or more [22], a SF-36 
physical function sub-scale score of 65 or less [23] and age at least 18 years old. 
Exclusion criteria were a significant risk of self-harm, being considered by the RA to 
be unable to participate in the trial, participation in the PACE trial being inappropriate 
for clinical needs, and patients who had previously attended a PACE centre specialist 
fatigue clinic and received a course of PACE trial consistent treatment [19]. 
The Structured Clinical Interview for DSM-IV was administered by the RA, 
after appropriate training, and used to assess psychiatric comorbidity and psychiatric 
exclusions [24]. Further baseline information collected included demographic details, 
current membership of a local or national ME self-help group, and body mass index 
(BMI). Additional self-report questionnaires included the Chronic Disease Self-
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Efficacy measure [25], physical symptoms (Patient Health Questionnaire; PHQ-15) 
[26], Cognitive Behavioural Responses Questionnaire  (CBRQ) [27], Jenkins sleep 
scale of subjective sleep problems [28], and the Hospital Anxiety and Depression 
Scale (HADS) [29]. Further assessments consisted of the International (CDC) criteria 
for CFS [12], the London criteria for myalgic encephalomyelitis [21] and presence or 
absence of fibromyalgia [30].  
 
Assessment of adverse events 
 Follow-up assessment interviews were conducted by the RA at each centre on three 
occasions: 12, 24 and 52 weeks after randomisation. At each of these time points the 
RA asked participants whether any new events or illnesses had taken place since the 
last assessment including any events for which the participant visited the GP or 
hospital department, or took medication. [19] AEs were also recorded by treating 
specialist doctors and therapists if spontaneously reported to them during the trial. An 
AE was defined as ‘any clinical change, disease or disorder experienced by the 
participant during their participation in the trial, whether or not considered related to 
the use of treatments being studied in the trial’ [19]. We did not examine inter-rater 
reliability between RAs since we did not foresee variability in these assessments.   
AEs included: (a) Any new co-morbid medical conditions reported, if not 
previously reported at baseline, (b) any events for which the participant consulted 
their GP or other medical advisor or took medication, and (c) any other events that 
might have affected the health status of the participant (e.g. increased work stress). 
Examples of NSAEs included a cold (which had not caused serious disability), an eye 
infection, or the experience of new pain (if not previously reported as a symptom of 
the participant’s CFS). If in doubt, the RA was encouraged to contact the GP for both 
an update of all visits to the surgery since the last research session and a list of any 
medications prescribed. The RA also took note of any new events recorded in the 
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clinic notes by the SMC doctor at these sessions or reports thereof from the treating 
specialist doctor or therapist.  
Two consultant physicians and a consultant liaison psychiatrist, all 
experienced in CFS, were appointed as independent scrutineers and were masked to 
the participants’ allocated treatment group. They determined whether each AE was 
serious or non-serious. A serious adverse event (SAE) was an event  that resulted in 
one of the following outcomes: a) death, b) threat to life (i.e., an immediate, not 
hypothetical, risk of death at the time of the event), c) required hospitalisation except 
for elective treatment of a pre-existing condition, d) increased severity and persistent 
disability, defined as: (i) severe, i.e. significant deterioration in the participant’s ability 
to carry out their important activities of daily living (e.g. employed person no longer 
able to work, caregiver no longer able to give care, ambulant participant becoming 
bed bound); and (ii) symptom and disability persistent, i.e. of at least 4 weeks 
continuous duration, e) any other important medical condition which, though not 
included in the above, might require medical or surgical intervention to prevent one of 
the outcomes listed, f) any episode of deliberate self-harm. For any AE established 
as serious, the scrutineers were unmasked to treatment allocation to establish 
whether or not the event was a serious adverse reaction (SAR). A serious adverse 
reaction was considered to be a reaction to one of the supplementary therapies or a 
drug prescribed as part of SMC [19]. All those judged as definitely, probably, or 
possibly related were considered to be SARs. 
A non-serious adverse event (NSAE) was any health event, which was not 
categorised as an SAE or SAR. Each NSAE was ascribed to the appropriate body 
system (gastroenterological, neurological, etc.) independently by two senior medical 
clinicians (one a consultant infectious diseases physician, the other a consultant 
liaison psychiatrist; both experienced in CFS), who were different from the 
independent scrutineers. NSAEs attributed to CFS (i.e. considered to be a symptom 
of CFS) were put into a separate category since there is no consensually agreed 
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body system for CFS, and because of specific interest in these symptoms. 
Differences in clinicians’ ratings were resolved by discussion until consensus was 
reached. To summarise, adverse events were any new health related event reported 
by the participant in any context. These were independently judged as serious 
adverse events, using an a priori guideline of seriousness, and as serious adverse 
reactions if independently judged to be a reaction to a trial intervention. 
 
Statistical analysis 
Firstly, the frequencies of NSAEs were reported by participant and then compared 
between treatment arms and centres by chi squared tests. Because there were 
individual differences between participants in the duration of follow up (depending on 
drop-outs) we calculated the number of NSAEs per person year of follow-up, and 
compared these across treatment arms. The distribution of NSAEs across trial 
participants was non-normal, and attempts to normalise the distribution by 
transformation were unsuccessful, so we used non-parametric comparisons, such as 
Kruskal-Wallis tests. We then compared the proportions of participants with NSAEs 
attributed to different body systems across treatment arms, with a chi squared test.  
A Poisson regression model was attempted with the frequency of NSAEs per 
participant, but this did not provide an adequate fit to the data due to the variance 
exceeding the mean (extra-Poisson variation);  a negative binomial model was 
uninformative. Instead we used a median split (4/5) of the numbers of NSAEs, 
determined by analysis of the frequency of NSAEs per participant, as well as CFS 
related NSAEs per participant (0/1) in order to examine univariate associations with 
baseline characteristics. There were no informative independent studies of non-
serious adverse events to guide us.  
Secondly, univariate analyses of associations between NSAEs and other 
variables were conducted, with continuous variables transformed when not normally 
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distributed. The chi-squared test was used for categorical variables. The t-test was 
used for continuous normally distributed variables.  
Thirdly, all associated univariate variables, significant at p≤0.1, were entered 
into a multivariate binary logistic regression model for all NSAEs, followed by a 
separate regression analysis for NSAEs attributed to CFS.  Age, sex and treatment 
arm were also entered into all models. We also modelled those with one or more 
NSAEs versus those without any, using a logistic regression analysis to establish 
characteristic differences between these two groups of patients.  
In order to provide further checks on the relatedness of adverse events in 
general to trial treatments, we compared both serious adverse events and reactions, 
and the numbers of participants in each treatment group who reported being “much 
worse” or “very much worse” in their overall health at 52 weeks after 
randomisation.[31] We also compared the numbers of participants in each treatment 
arm who had deteriorated by more than a clinically important difference (at least 2 
points on the fatigue questionnaire and/or at least 8 points on physical function, 
which represented 0.5 of a standard deviation of baseline outcome measures) 
between randomisation and 52 weeks later [17]. We then examined the number of 
NSAEs in those who had deteriorated by either of the latter measures. We analysed 
the data using SPSS v18 and v22. 
As a post hoc analysis, in order to better understand the differences in NSAE 
counts between centres, we stratified centres into three groups: low (3 centres), 
medium (2 centres) and high (1 centre) numbers of NSAEs per participant. Using 
these strata, we undertook a one way analysis of variance (ANOVA) of those 
continuous variables that showed statistically significant differences by NSAE count 
on univariate analyses. We examined linear trends across centre strata.  
 
Results 
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Most (77%) participants were female, with only 7% from ethnic minorities. The mean 
(SD) age of participants was 38 (12) years. Approximately half of participants were 
educated to A-level or degree level standard (appendix table A). One participant 
withdrew their consent after participation, leaving 640 in the analysis. 
The median (quartiles) number of reported NSAEs per participant per annum 
was 4 (2, 8), with no significant difference between treatment arms (Kruskal-Wallis 
test p = 0.47) (table 1). This median was used to divide the sample into those with 
lower (≤ 4) and higher (≥ 5) numbers of NSAEs for the purpose of binary logistic 
regression analyses. The number (%) of trial arm participants with more than the 
median number of NSAEs varied from 78 (49%), in those allocated to CBT, to 90 
(56%) in those allocated to GET (X2 = 2.34, 3 df, p < 0.51) (table 1). Figure 1 shows 
that the distributions of NSAE counts had similar patterns across the treatment 
groups, but with more participants having no NSAEs  in the CBT group (post hoc 
comparison of CBT participants versus all others combined: 6% versus 11%, chi-
squared = 4.65, 1 df, p = 0.03). 
A highly statistically significant difference in the reporting of NSAEs between 
trial centres was found (p <0.001). This varied from a median of 4  in one centre  to 
10 in another centre (appendix table B).  
 
Types of NSAE  
NSAEs affecting eyes, ears, nose and throat were reported by 54% of  participants, 
with 46% of participants reporting NSAEs attributed to CFS (table 2). Smaller 
numbers of participants had gastrointestinal, psychiatric/psychological and 
musculoskeletal NSAEs (table 2). Chi squared tests showed no statistically 
significant differences in any of the comparisons across the four treatment arms 
(table 2).   
 
Univariate associations 
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There were no significant associations of NSAEs with socio-demographic 
characteristics (appendix, table A). In contrast, there were significant associations 
between increased reporting of NSAEs and several baseline variables: the numbers 
of both physical symptoms in general and symptoms of CFS, higher BMI, worse 
physical function, avoidance due to embarrassment, more fatigue, and HADS 
depression (table 3). The mean (standard deviation) BMI was 25.5 (4.97) for all 640 
participants. Some 123 (19%) participants were morbidly obese (BMI ≥ 30). 
Significant associations were also found between reporting more NSAEs and having 
any psychiatric disorder, particularly depressive disorder, dysthymia, and major 
depressive disorder (table 4). There were no significant associations with anxiety 
disorders.  
 
Multivariable binary logistic regression of NSAEs  
When modelling all NSAEs, using a median split of 4 or less versus 5 or more, centre 
effects dominated the models, so we remodelled both with and without centre. 
Without centre, a larger number of NSAEs was associated with baseline CFS 
symptom count (odds ratio (OR, 95%CI) 1.12 (1.01, 1.24), p = 0.03), physical 
symptom count 1.04 (0.99, 1.08), p = 0.09, baseline current depressive disorder 1.47 
(1.04, 2.07), p = 0.03, and log body mass index 2.55 (1.09, 5.96), p = 0.03. With 
centre included, depressive disorder was lost from the model, as was the number of 
physical symptoms, but CFS symptoms (p < 0.001) and BMI (p = 0.035) were 
retained. There was no significant interaction between centre and treatment arm 
when this interaction term was entered into the model, indicating no differential 
effects of centre on treatments. 
The one factor associated with one or more versus no NSAEs was CFS 
symptom count (1.17 (0.99, 1.38), p = 0.065).  Adding centre to the model retained 
CFS symptom count (p = 0.01) and added treatment arm, but only at a p value of 
0.10. 
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Multivariable binary logistic regression of CFS related NSAEs 
CFS related NSAEs were associated with baseline depressive disorder (1.81 (1.29, 
2.53), p = 0.001) and baseline CFS symptom count (1.13 (1.03, 1.24), p = 0.008). 
Adding centre replaced baseline depressive disorder with baseline major depressive 
episode (p = 0.03) and added physical symptom count (p = 0.09) as well as CFS 
symptom count (p = 0.006).  
 
Post hoc exploration of centre effects on NSAE count 
Seven of ten variables measured at baseline were significantly correlated in a linear 
trend with centres stratified by NSAE count in the ANOVA (appendix table B). 
However, the variation between mean scores per centre varied little, with the most 
significant different variables of Chalder fatigue, SF36, and PHQ15 varying by 2, 6 
and 2.8 points respectively. There were no significant correlations for age, sex, 
duration of illness, and embarrassment scores.  
 
Deterioration by other measures 
Table 5 shows that there were no statistically significant differences between 
treatment arms in those who had an SAE, SAR, or in those who had deteriorated 
either by CGI score (of either “much” or “very much worse”). This was also the case 
for fatigue alone and fatigue and disability combined. Similarly, there were no 
significant differences across treatment arms between the median number of NSAEs 
in those who had deteriorated as measured by the global impression change score (p 
= 0.97) and those reporting deterioration in both primary outcomes of fatigue and 
physical disability (p = 0.16) between treatment groups. However, there was a 
significant difference in deterioration of physical function, across treatment arms, with 
a quarter of those who received APT deteriorating, compared to 18% after SMC, and 
11% and 9% after GET or CBT respectively. 
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Discussion 
There were no important differences between treatment arms in any of the adverse 
events, however they were measured or classified. Most importantly there was no 
evidence of more frequent adverse events after either CBT or GET. The factors 
associated with a higher number of NSAEs were the centre where the participant 
was seen, followed by the number of physical symptoms at baseline, having a 
depressive episode, and higher body mass index. Those variables associated with 
CFS related NSAEs were centre, CFS symptom count and a depressive episode. 
The common baseline associations in both models were centre, depressive disorder 
and physical symptom count. Those who received APT were most likely to 
deteriorate by a clinically important amount in physical function, with those in receipt 
of CBT being least likely to deteriorate. 
The substantial variation in the frequency of the reporting of NSAEs between 
centres is our most unexpected finding, although variation between centres is not 
uncommon in multi-centre trials [32], and this did not influence treatment response 
[17]. We found statistically significant linear associations between centres stratified 
by NSAE counts and a number of baseline variables, but the differences between 
centres were small, and nothing like the size of differences in NSAE frequency 
across centres. ThIs suggests that the large differences in NSAE numbers between 
centres is unlikely to be related to the small differences found between centres in 
baseline factors. Although the research assessments across centres were 
standardised and training was provided at the start of the trial, it might be that the 
differences were due to different methods of ascertainment. This apparent variation 
in recording NSAEs, despite a standard protocol for doing so, has important 
implications for recording adverse events in future trials.  
Having more symptoms at baseline, particularly those associated with CFS, 
predicted subsequent NSAEs in general and also NSAEs attributed  to CFS. This 
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replicates previous work [5]. Higher symptom counts are associated with somatoform 
disorders in secondary care [33], and may reflect a general tendency to report 
symptoms, which is associated with, but also independent of, mood disorders [34]. 
The specificity of CFS symptoms at baseline being associated with  NSAEs attributed 
to CFS suggests a specific tendency to report these symptoms, rather than a generic 
influence of reporting any symptom. It may also reflect the relapsing and remitting 
nature of CFS. 
Our finding that a  diagnosis of a depressive disorder at baseline predicted 
increased reporting of NSAEs is consistent with previous studies that found negative 
affect to be associated with NSAEs specifically [1,3], and somatic symptoms in 
general [6-10, 35]. This association remained significant for both NSAEs as a whole 
and for CFS attributed NSAEs in one regression model. Unlike some previous 
studies, we did not find an association with anxiety, either with the HADS score or 
through the SCID interview. One other trial failed to find an association between 
anxiety and adverse events [5].  
We found that a higher BMI was associated with NSAEs in general. This 
observation may have several explanations; obese people generally report both more 
physical and mental health related problems [36], and our sample included 123 
(19%) participants who were morbidly obese. We were not able to replicate a 
previous research finding that female participants are more likely to report adverse 
events [4].  
The strengths of this paper are that it used data from a large trial from 
multiple centres. The assessment of NSAEs on three occasions improved sensitivity. 
The limitations include the difference in frequency of NSAE reporting between 
centres, implying variation in ascertainment, although controlling for centre did not 
significantly affect our main findings. We only measured deterioration using self-
ratings, rather than objective measures. We were unable to model the full distribution 
of NSAEs, which may have limited the power of our regression models. 
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Conclusions 
We found that there were no important differences in any of the adverse events 
between treatment arms, and no excess associated with either CBT or GET. 
Clinically important deterioration occurred least often after CBT and GET; APT may 
be associated with more frequent deterioration in physical functioning. We also noted 
that the reporting of non-serious adverse events in a clinical trial of treatment for CFS 
varied by recruitment centre, perhaps related to the method of ascertainment. This 
important finding has implications for the design of future trials. Research assessors 
need clear manualised guidance on the various definitions of adverse events, and 
specific training and supervision in order to implement them. We also found that 
baseline symptom count, having a depressive disorder and BMI were significantly 
associated with a greater number of NSAEs, independently of the  treatment arms. 
This has both research and clinical implications for clinicians running trials, 
particularly those including patients with CFS. Adverse events in trials may more 
accurately reflect fluctuations in a condition, rather than reactions to interventions.  
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Figure 1. Histograms of non-serious adverse events by treatment arm 
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Table 1 
 Non-serious adverse events (NSAEs) by treatment arm N (%) 
Treatment 
N 
APT CBT GET SMC 
159 161 160 160 
Participants with NSAEs 152 (96) 143 (89) 149 (93) 149 (93)* 
Number of NSAEs 949 848 992 977 
Median (quartiles) 
NSAEs per person-year 
4 (2, 9) 4 (2, 7) 5 (2, 8) 4 (3, 8)# 
N (%) > median number 
of NSAEs 
81 (50) 78 (49) 90 (56) 79 (49)¶ 
 
APT = Adaptive pacing therapy, CBT = Cognitive behavioural therapy, GET = 
Graded exercise therapy, SMC = Standardised specialist medical care. *X2 = 5.61, 3 
df, p = 0.13. #Kruskal-Wallis test of differences between treatment arms p = 0.47. ¶X2 
= 2.34, 3 df, p =< 0.51. 
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Table 2 
Numbers (%) of participants with one or more non-serious adverse events by body 
system  
Body system 
             Trial Arm % X2 P 
APT 
(159) 
CBT 
(161) 
GET 
(160) 
SMC 
(160) 
 
 
 
Eyes & ENT 91 (57) 87 (54) 81 (51) 87 (54) 54 1.41 0.70 
CFS/ME/PVFS 73 (46) 66 (41) 79 (49) 76 (48) 46 2.50 0.47 
Gastro-intestinal 59 (37) 57 (35) 53 (33) 67 (42) 37 2.84 0.42 
Psychol/psychiatric 57 (36) 56 (35) 47 (29) 52 (33) 33 1.78 0.62 
Musculo-skeletal 56 (35) 47 (29) 53 (33) 41 (26) 31 4.07 0.25 
Obs/Gynae/Urinary 40 (25) 34 (21) 34 (21) 33 (21) 22 1.22 0.75 
Respiratory 34 (21) 30 (19) 36 (23) 49 (31) 22 7.15 0.067 
Dermatological 33 (21) 21 (13) 30 (19) 35 (22) 19 4.91 0.18 
Neurological 26 (16) 26 (16) 31 (19) 39 (24) 19 4.58 0.21 
Stressful events 18 (11) 17 (11) 26 (16) 19 (12) 13 2.87 0.41 
Cardiovascular 8 (5) 11 (17) 8 (5) 11 (7)   6 0.97 0.81 
Nutrient & blood 5 (3) 2 (1) 8 (5) 3 (2)   3 4.83 0.18 
Allergies 2 (1) 6 (4) 6 (4) 4 (3)   3 2.47 0.48 
Endocrine 8 (5) 4 (2) 1 (1) 3 (2)  3 6.74 0.081 
Miscellaneous 4 (3) 5 (3) 3 (2) 8 (5)  3 2.88 0.41 
 
The table gives the number (%) of participants having one or more non-serious adverse 
events during their participation in the trial, separated into individual body systems. APT 
= Adaptive pacing therapy, CBT = Cognitive behavioural therapy, GET = Graded 
exercise therapy, SMC = Standardised specialist medical care. ENT = Ear, nose and 
throat. CFS = Chronic fatigue syndrome, ME = myalgic encephalomyelitis, PVFS = post-
viral fatigue syndrome.  
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Table 3 
Univariate comparisons of baseline variables in those below & above median number of non-
serious adverse events (NSAEs) 
Variable 
 
NSAE ≤4 
 (N 313) 
NSAE >4  
(N 327) 
Mean SD Mean SD t p 
CFS symptom count 4.4 1.8 4.9 1.8 3.87 <0.001 
PHQ-15  13.5 4.3 14.8 4.8 3.63 <0.001 
BMI 25.0 4.8 25.9 5.1 2.40 0.02 
SF 36-PF  39.6 15.2 36.5 16.2 2.48 0.01 
CBRQ embarrassment 11.6 5.5 12.6 5.5 2.33 0.02 
Fatigue 27.8 3.7 28.5 3.8 2.15 0.03 
HADS depression 8.0 3.6 8.6 3.9 2.14 0.03 
HADS anxiety 7.7 4.2 8.3 4.3 1.80 0.07 
CBRQ all or nothing 13.6 3.8 14.1 3.8 1.57 0.12 
CBRQ catastrophising 7.6 3.4 8.0 3.3 1.54 0.12 
WSAS 26.9 6.3 27.6 6.3 1.39 0.16 
Jenkins sleep  11.9 4.8 12.4 4.8 1.23 0.22 
Self-efficacy 4.8 1.5 4.7 1.6 0.86 0.39 
CBRQ behaviour avoidance 18.8 4.9 19.2 5.2 0.56 0.58 
CBRQ symptom focusing 12.8 4.9 13.0 5.0 0.51 0.61 
CBRQ fear avoidance 15.2 4.0 15.1 3.9 0.19 0.85 
CBRQ damage 11.0 3.4 11.0 3.3 0.025 0.98 
 
CFS = chronic fatigue syndrome, PHQ = Patient Health Questionnaire, BMI = body mass 
index, SF-36 PF = Short form 36 item physical function, HADS = Hospital Anxiety Depression 
Scale, CBRQ = Cognitive Behavioural Responses Questionnaire, WSAS = Work and Social 
Adjustment Scale.  
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Table 4 
Association of baseline diagnoses with number of NSAEs below and above median 
N (%) 
 NSAE ≤ 4 NSAE > 4 X2 P 
Total  313 49% 327 51%   
London ME case       
      Met (329) 177 56 152 46 6.49 0.011 
      Not met (311) 136 44 175 54   
All psychiatric diagnoses       
Present (299) 128 41 171 52 8.35 0.004 
None (341) 185 59 156 48   
All depressive disorders       
Present (213) 85 27 128 39 10.35 0.001 
None  (427) 228 73 199 61   
Major depressive disorder       
Present (112) 44 14 68 21 5.03 0.025 
None (528) 269 86 259 79   
Minor depressive disorder       
Present (67) 28 9 39 12 1.52 0.220 
None (573) 285 91 288 88   
Dysthymic disorder       
Present (71) 24 8 47 14 7.29 0.007 
None (569) 289 92 280 86   
All anxiety disorders       
Present (202) 92 29 110 34 1.33 0.250 
None (438) 221 71 217 66   
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Generalised anxiety disorder       
Present (132) 56 18 76 23 2.80 0.094 
None (508) 257 82 251 77   
Fibromyalgia       
Present (138) 69 22 69 21 0.07 0.79 
None (501) 244 78 257  79   
SAEs or SARs during follow-up 
      
Present (51) 20 6 31 9 2.08 0.15 
None (589) 293 94 296 91   
All depressive disorders included major and minor depressive disorder and 
dysthymia. All anxiety disorders included generalised anxiety disorder, panic 
disorders, phobias and post-traumatic stress disorders. SAEs + SARs = Number of 
participants with one or more serious adverse events or reactions. 
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Table 5 
Serious adverse events/reactions and deterioration by 52 weeks (N %) 
Treatment (N) APT 
159 
CBT 
161 
GET 
160 
SMC 
160 
Chi-sq P 
Serious adverse events 15 (9) 7 (4) 13 (8) 7 (4) 5.3 0.15 
Serious adverse reactions 2 (1) 3 (2) 2 (1) 2 (1) 0.3 0.96 
Physical function worse 39 (25) 15 (9) 18 (11) 28 (18) 17.2 0.0007 
Fatigue worse 21 (13) 14 (9) 11   (7) 22 (14) 5.8 0.12 
Function & fatigue worse 11   (7) 4   (2) 5   (3) 8   (5) 4.6 0.21 
Median (quartile) NSAEs  
in those worse 
8 (4, 
11) 
3 (2, 5) 7 (4, 
14) 
4 (3, 12) 
 
0.16 
CGI worse 10   (6) 9   (6) 10   (6) 14   (9) 1.5 0.69 
Median (quartile) NSAEs  
in those worse by CGI 
6 (4, 8) 8 (2, 11) 6 (2, 
17) 
4 (3, 14) 
 
0.97 
Physical function worse = SF36 sub-scale score 8 or more points’ deterioration; 
Fatigue worse = Chalder fatigue questionnaire score 2 or more points’ deterioration, 
CGI = Clinical Global Impression change = “much” or “very much” worse. , APT = 
Adaptive pacing therapy, CBT = Cognitive behavioural therapy, GET = Graded 
exercise therapy, SMC = Standardised specialist medical care. 
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APPENDIX 
Table A 
Sociodemographic characteristics: Univariate comparisons 
Number of reported adverse 
events 
NSAE ≤4   NSAE >4 
N % N % X2 P 
Total (N) 313 49 327 51   
Gender (1 df)       
Female (495) 237 76 258 79 0.92 0.34 
Male (145) 76 24 69 21   
Ethnicity (1 df)       
Other (40) 20 6 20 6 0.038 0.84 
White (595) 288 94 307 94   
Educational level (5 df)       
Minimal (24) 17 5 7 2 6.51 0.26 
GCSE/equivalent (110) 47 15 63 19   
A level/equivalent (127) 64 20 63 19   
Degree (198) 96 31 102 33   
Postgraduate (114) 57 18 57 17   
Other (67) 32 10 35 11   
ME group member (3 df)       
Local only (33) 16 5 17 5 4.3 0.23 
National only (54) 20 7 34 10   
 Both (18) 11 4 7    
No group (535) 266 50 269 82   
 Mean SD Mean SD t p 
Age at randomisation (years) 38.4 11.6 38.3 12.1 0.014 0.79 
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Table  B 
Variation of The reporting of non-serious adverse eventsNSAEs and baseline variables by centre 
(N %) 
 
 
 
AKings BOxford CBart’s DEdinburgh 
ERoyal 
Free 
FBristol P value 
Median 
(quartiles) 
NSAE 
count 
3 (1, 4) 3 (2, 5) 4 (2, 6) 7 (4, 10) 8 (4, 13) 
10 (6, 
15) 
<0.001* 
NSAE ≤4 
(313) 
86 (78) 74 (69) 78 (58%) 38 (34) 32 (29) 5 (8)  
NSAE >4 
(327) 
24 (22) 34 (31) 57 (42%) 75 (66) 79 (71) 58 (92) 
< 
0.0001# 
Total 110 108 135 113 111 63  
Chalder 
fatigue 
28.5 
(3.6)¶ 
28.1 
(3.4) 
27.2 
(4.1) 
28.8 (3.6) 
28.0 
(3.9) 
29.2 
(3.5) 
0.005$ 
SF36 PF 39 (16) 40 (16) 41 (13) 36 (16) 35 (16) 37 (16) 0.006 
CFS 
symptoms 
5.0 (1.7) 4.6 (1.7) 4.3 (1.8) 4.6 (1.8) 4.7 (1.8) 5.4 (1.8) 
0.01 
HADS 
anxiety 
7.7 (4.4) 7.3 (3.7) 8.1 (4.6) 7.9 (4.2) 8.4 (4.2) 9.3 (3.8) 
0.008 
HADS 
depression 
8.3 (3.5) 7.6 (3.2) 8.2 (3.8) 8.4 (4.0) 8.4 (4.0) 9.4 (4.2) 
0.02 
PHQ15 14.4 
(3.9) 
13.8 
(4.3) 
12.9 
(4.4) 
14.2 (4.2) 
14.8 
(5.2) 
15.7 
(5.5) 
<0.001 
BMI 25.2 
(4.7) 
27.0 
(5.5) 
24.0 
(5.5) 
25.5 (4.7) 
25.1 
(5.0) 
27.2 
(5.3) 
0.04 
* Kruskal-Wallis. # χ2 (5 df) = 129.4, p <0.0001. NSAE = Non-serious adverse events. SF36 PF = 
SF36 physical function sub-scale score. HADS = Hospital Anxiety Depression scale. PHQ15 = 
Patient Health Questionnaire. ¶ Last seven lines show means (SD). $ The comparisons were by 
one way ANOVA across the centre strata of low, medium and high NSAE counts, with linear test 
for trend. 
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Highlights 
• This study shows the distribution of adverse events in a trial of treatments for CFS. 
• Non-serious adverse events were common, but no different between treatments. 
• Non-serious adverse events were more related to ill health than treatments. 
• Deterioration in physical function was more likely after adaptive pacing therapy. 
• Differences between centres may be related to different ascertainment methods. 
 
